Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 26,886 | 26,070 | 51,278 | 22,410 | 29,819 |
| Cost of Goods | 1,075 | 977 | 342 | 250 | 1,036 |
| Gross Profit | 25,811 | 25,093 | 50,936 | 22,160 | 28,783 |
| Operating Expenses | 31,153 | 38,795 | 49,199 | 40,813 | 41,784 |
| Operating Income | -5,267 | -12,725 | 2,079 | -18,403 | -12,965 |
| Interest Expense | 1,862 | 1,204 | 1,107 | 826 | 569 |
| Other Income | 529 | 393 | 429 | 192 | 42 |
| Pre-tax Income | -6,600 | -13,536 | 1,401 | -19,037 | -13,492 |
| Net Income Continuous | -6,600 | -13,536 | 1,401 | -19,037 | -13,492 |
| Net Income | $-6,600 | $-13,536 | $1,401 | $-19,037 | $-13,492 |
| EPS Basic Total Ops | -0.38 | -0.80 | 0.06 | -1.10 | -0.80 |
| EPS Basic Continuous Ops | -0.38 | -0.78 | 0.05 | -1.10 | -0.78 |
| EPS Diluted Total Ops | -0.38 | -0.80 | 0.06 | -1.10 | -0.80 |
| EPS Diluted Continuous Ops | -0.38 | -0.78 | 0.05 | -1.10 | -0.78 |
| EBITDA(a) | $-5,017 | $-12,436 | $2,184 | $-18,154 | $-12,649 |